ASX & Press Releases

Tuesday, February 11, 2014

Mr Costa's appointment brings to Alchemia extensive international experience, with over 30 years in senior leadership roles including President and Chief Operating Officer of Quintiles Transnational Corp.

Monday, January 13, 2014

Charles Walker, CEO, provides an update to investors on fondaparinux, HA-Irinotecan and the oncology portfolio.

Monday, December 16, 2013

Thomas brings significant pharmaceutical industry skills and experience to Alchemia and is an exceptional appointment to the Company as it looks to build value for the future. Mr. Liquard will be responsible for managing commercial and corporate development, in addition to assuming a range of other responsibilities across the organization

Thursday, November 28, 2013

CEO Charles Walker provides an update on the sales of fondaparinux in his latest investor update

Friday, November 1, 2013

Dr Reddy’s reports significant traction in market share of fondaparinux in the U.S., with Canadian launch expected in the coming months. In addition, two new approval applications were filed, and four additional applications to be filed in 2014. EU approval expected late 2014/2015.

Tuesday, October 29, 2013

The company provides an update on HA-Irinotecan and the small cell lung cancer trial, and receipts from the Governments R&D tax incentive

Tuesday, October 8, 2013

Alchemia has released its 2013 Annual Report, which can also be viewed directly from our website.

Thursday, September 19, 2013

Pages